News and Comments

BIOTECHNOLOGY PROMISES A HUGE GROWTH

  Wednesday, December 21, 2011

EXELIXIS’ (EXEL) advanced PI3K-delta research and development preclinical program attracted Merck, known as MSD outside of the United States and Canada. “PI3K-delta is therapeutic target that academic researchers and the drug industry are racing to develop therapeutic antagonists for both inflammatory diseases and cancer. To get to Exelixis program, Merck agreed to pay $12 million in upfront payment in addition to potential milestone payments for multiple indications of up to $239 million and royalties on net-sales of products that would emerge from the agreement. Merck will also pay Exelixis royalties on any compounds that would emerge from Exelixis’ PI3K-delta program or from certain compounds that arise from Merck’s internal discovery efforts targeting PI3K-delta during a certain period. More...


Recent Postings


Archive


Tags

Human Longevity (HLI) SYNTA (SNTA) RenenxBio (RGNX) GUARDIAN HEALTH Velcade (bortezomib) ImmunoGen (IMGN) Tysabri Vertex (VRTX) Elan (ELN) Trastuzumab-DM1 Ridaforolimus Telaprevir Jazz Pharmaceuticals (JAZZ) Anacor (ANAC) Dendreon (DNDN) Amgen (AMGN) ZALTRAP™ VANDA (VNDA) IDERA (IDRA) Merck (MRK) Multiple Myeloma Editas (EDIT) Sequenom (SQNM) Agenus (AGEN) Inovio (INO) HALOZYME (HALO) Sangamo (SGMO) Galena (GALE) Endometrial Cancer Exelixis (EXEL) NANTKWEST (NK) KITE (KITE) ADVENTRIX (ANX) Agenus (AGEN Idenix (IDIX) Zerenex Array Pharmaceuticals (ARRY) SERES THERAPEUTICS (MCRB) Aimmune Therapeutics (AIMT) Human Genome Sciences (HGSI) Spike Therapeutics (ONCE) KERYX (KERX) Ariad (ARIA) Anadys (ANDS) Vitae Pharmaceuticals (VTAE) ARCA (ABIO) Abbott Laboratories (ABT) NEKTAR (NKTR)) Herceptin GlaxoSmithKline (GSK) Intercept (ICPT) MODERNA JUNO (JUNO) C4 Therapeutics ACADIA (ACAD) Intermune (ITMN) NOVOCURE (NVCR) Theravance Bio Pharma (TBPH) Ziofpharm (ZIOP) Cytokinetics (CYTK) Sanofi (SNA) SUNESIS PHARMACEUTICALS (SNSS) Prosensa (RNA) Rapamune Dynavax (DVAX) Genentech Prolor Biotech (PBTH) BIOMARIN (BMRN) Biogen Idec (BIIB) Alnylam (ALNY) Onyx (ONXX) Global Cell Therapeutics (GBT) Benlysta (belimumab) Gilead (GILD) Bellicum (BLCM) AGOS (ARGS) Revlimid (lenolidamide) Mirati Therapeutics (MRTX) Illumina (ILMN) Incyte (INCY) Micromet (MITI) Intrexon (XON) Regeneron (REGN) Ionis (IONS) Sarepta (SRPT) CRISPR Therapeutics (CRSP) TOKAI (TKAOI) Alder Biopharmaceuticals (ALDR) Auspex (ASPX) Advaxis (ADXS) Pluristem (PSTI) Roche (RHHBY) CompuGen (CGEN) REGULUS (RGLS) Bristol-Myers Squibb (BMY) PTC Therapeutics (PTCT) Sanofi-Aventis (SAN) Sanofi (SNY) OSI (OSIP) ISIS (ISIS) galapagos (GLPG) Xoma (XOMA) Valeant Pharmaceuticals International (VRX) ARGOS (ARGS) Theravance (THRX) INNOVIVA (INVA) Biocryst (BCRX) AERIE PHARMACEUTICALS Adaptimmune (ADAP) ABBVIE (ABBV) AstraZeneca (AZN) Roche (ROCHE) Seattle Genetics (SGEN)